

Effect of simvastatin on endothelial dysfunction, fibrinolysis, coagulation and inflammation after aneurysmal subarachnoid hemorrhage

Submission date 29/06/2006	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 29/06/2006	Overall study status Completed	☐ Protocol
Last Edited 02/09/2009	Condition category Nervous System Diseases	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr M.D.I. Vergouwen

Contact details
Academisch Medisch Centrum
Afdeling Neurologie H2
Meibergdreef 9
Amsterdam
Netherlands
1105 AZ
+31 (0)20 5663842
m.d.vergouwen@amc.uva.nl

Additional identifiers

Protocol serial number
NTR668

Study information

Scientific Title

Study objectives

In patients with aneurysmal subarachnoid hemorrhage (SAH), simvastatin restores endothelial cell damage, activates fibrinolysis, and improves coagulation and inflammation after the hemorrhage.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from local medical ethics committee

Study design

Randomised double blind placebo controlled parallel group trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Aneurysmal subarachnoid hemorrhage

Interventions

Patients will receive simvastatin 80 mg a day or placebo until day 14 after aneurysmal subarachnoid hemorrhage.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Simvastatin

Primary outcome(s)

1. The effects of simvastatin on the parameters of fibrinolysis, coagulation, inflammation and endothelial function after SAH
2. The relation between changes in fibrinolytic activity and endothelial cell damage and activation

Key secondary outcome(s)

1. The occurrence of cerebral ischemia after SAH
2. Outcome on the Glasgow Outcome Scale and Academic Medical Center Linear Disability Scale (ALDS) three and six months after subarachnoid hemorrhage
3. The relation between vasospasm as observed on transcranial Doppler examination and

parameters of fibrinolysis, coagulation, endothelium dysfunction and inflammation

4. The relationship between cerebral ischemia as observed on perfusion CT-scans and parameters of fibrinolysis, coagulation, endothelium dysfunction and inflammation
5. The relationship between plasminogen activator inhibitor type-1 (PAI-1) polymorphism and fibrinolysis in patients treated with simvastatin and placebo
6. The relationship of polymorphisms in the endothelin system on endothelial cell damage
7. Differences in cerebral microcirculation between patients treated with placebo and simvastatin

Completion date

01/11/2007

Eligibility

Key inclusion criteria

1. Patients with clinical symptoms and signs of SAH with an aneurysmal bleeding pattern on the initial computerised tomography (CT) scan. CT scan has to be performed within 48 hours after SAH onset
2. Patients with a perimesencephalic hemorrhage pattern on the initial CT scan while computed tomographic angiography (CTA) or conventional angiography has shown an appropriate aneurysm. CTA or angiography has to be performed within 48 hours after SAH onset
3. If CT scan is negative while there is evidence of bleeding in the cerebrospinal fluid (xanthochromia) and the CT-angiography has shown an aneurysm

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Under 18 years of age
2. A time lapse of more than 48 hours after SAH onset
3. Patients using aspirin or warfarin
4. Patients already using statins
5. Contra-indication for simvastatin (active liver disease, liver transaminase more than three times the normal upper limit, myopathy)
6. Kidney insufficiency
7. If death appears imminent
8. Pregnancy or lactation

Date of first enrolment

01/05/2006

Date of final enrolment

01/11/2007

Locations

Countries of recruitment

Netherlands

Study participating centre

Academisch Medisch Centrum

Amsterdam

Netherlands

1105 AZ

Sponsor information

Organisation

Academic Medical Centre (AMC) (The Netherlands)

ROR

<https://ror.org/03t4gr691>

Funder(s)

Funder type

University/education

Funder Name

Academic Medical Centre (AMC) (Netherlands) - Department of Neurology

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

[Results article](#)

results

01/08/2009

Yes

No